Sponsor
Rand Paul
Senator · R-KY
Senator · R-KY
The bill increases pricing freedom and reduces criminal liability for businesses, but does so at the risk of weakening federal deterrence against anticompetitive pricing—potentially harming small competitors, raising long-term consumer prices, and shifting enforcement costs to states and private parties.
Retailers and manufacturers (including some small sellers) gain broader pricing flexibility: businesses can offer discounts, rebates, or below-cost sales with fewer federal restrictions.
Business owners (particularly small-business owners) face reduced criminal exposure: removing criminal penalties lowers the risk of fines or imprisonment for aggressive pricing tactics.
Small businesses and local suppliers are more likely to be undercut: larger firms can use discriminatory discounts to take sales and market access from smaller rivals.
Consumers risk higher prices later if dominant firms engage in predatory pricing: removing deterrents can enable firms to drive rivals out and then raise prices.
Small businesses and consumers lose a federal deterrent against anticompetitive conduct: removing the criminal enforcement tool shifts enforcement to slower, costlier civil actions.
Based on analysis of 2 sections of legislative text.
Repeals the Robinson–Patman Act provisions that prohibited discriminatory pricing and below-cost sales and removes related criminal penalties.
Official title: Repeal the Robinson-Patman Act of 1936.
Introduced June 17, 2025 by Rand Paul · Last progress June 17, 2025
Repeals the 1936 Act that added provisions to the Robinson–Patman Act, removing the federal prohibition on discriminatory price concessions and below-cost sales that target competitors, and eliminating the associated criminal penalties. The change would allow manufacturers, wholesalers, and retailers greater freedom to offer different prices, discounts, or below-cost sales without the specific federal penalty that previously applied to those practices. The immediate legal effect is narrow and technical — it removes the statutory prohibition and criminal penalty that covered discriminatory pricing — but the practical consequences could be significant for drug manufacturers, pharmacies, hospitals, and consumers because pricing practices and competition rules would change for prescription drugs and other goods covered by the statute.